NCT04006535 (FAMILYVASC) is a clinical trial of genetic analysis in Vasculitis, sponsored by Benjamin Terrier.

Who is sponsoring NCT04006535?

NCT04006535 is sponsored by Benjamin Terrier.

What drugs are being tested in NCT04006535?

Interventions in NCT04006535: genetic analysis.

What condition does NCT04006535 study?

NCT04006535 studies Vasculitis.

Is NCT04006535 still recruiting?

NCT04006535 is currently recruiting now. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT04006535: FAMILYVASC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis

Recruiting now Last updated 8 July 2019

What this trial tests

trial testing genetic analysis in Vasculitis in 100 participants. Currently enrolling.

Timeline

1 June 2019

Primary endpoint
1 June 2029

1 June 2029

Quick facts

Lead sponsor	Benjamin Terrier
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 June 2019
Primary completion	1 June 2029
Estimated completion	1 June 2029
Sites	1 location across France

Drugs / interventions tested

genetic analysis

Conditions studied

Vasculitis — all drugs for Vasculitis →

Sponsor

Benjamin Terrier

Who can join

Eligibility, any sex, with Vasculitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The FAMILYVASC study is a prospective observational study which will aim to identify susceptibility loci and genes for systemic vasculitis risk in patients with familial or pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be carried out through salivary DNA.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of genetic analysis

Trials testing the same drug.

NCT04751058 — Genetic Profile in Patients With Aortic Syndrome · completed
NCT03580785 — Primary Failure of Eruption (PFE) : Highlighting of Clinical, Radiological and Genetic Diagnostic Criteria: Consequences · NA · recruiting

Other recruiting trials for Vasculitis

Currently open trials in the same condition.

NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
NCT06779799 — Characterization of "Bamboo" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune · recruiting
NCT06698614 — MEMRI and Kidney Disease · recruiting
NCT06321601 — Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Ye · Phase 3 · recruiting
NCT05734404 — Longitudinal Study for Central Nervous System Vasculitis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04006535 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Benjamin Terrier
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04006535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing